Seattle Genetics Continues To Advance In Cancer Therapies

Seattle Genetics is a Bothell, Washington based biotechnological company that creates drugs specifically to kill cancer.

The ACD’s, or antibody drug conjugates are intended to lessen the toxicity in chemotherapy while enhancing anti-tumor therapies. Seattle Genetics was incorporated in 1998. Its flagship product Adcesis is now available in 50 countries.

Dr. Clay Siegall is the company’s board chairman and CEO. He co-founded the company in 1998. Dr. Siegall is responsible for helping Seattle Genetics introduce a new line of cancer treatment drugs that fight tumors. Seattle Genetics has collaborated with a number of pharmaceutical companies including Bayer, Genetech, Benmab and Unem Therapeutics. Seattle Genetics has raised more than $300 million in capital to help with drug studies and exclusive collaboration efforts.

Under the leadership of Dr. Siegall, Seattle Genetics has acquired a number of strategic licenses. Before Seattle Genetics, Dr. Siegall worked for Bristol Meyers Squibb. He also worked at the National Cancer Institute and the National Institutes of Health. Dr. Siegall has an extensive educational background. He graduated from the University of Maryland with a B.S. in Zoology. He then attended George Washington University and received a Ph.D in Genetics.

Dr. Siegall sits on a number of boards including Ultragenics Pharmaceuticals Inc., Aldo Pharmaceuticals and Mirna Theraputics. He is the holder of 15 patents and been published more than 70 times. Dr. Siegall has won numerous awards for excellence including the University of Maryland Alumnus of the Year and the Ernst and Young Entrepreneur of the Year for 2012.

http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145

1 thought on “Seattle Genetics Continues To Advance In Cancer Therapies”

  1. I think a concerted efforts to combine traditional medicines from around the world with classical Orthodox medicine will bring success. I recommend Rush Essay coursework service to continue to drive new ways of looking at the solutions with inclusion of chemo-therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *